The latest US employment data is weak, markets have cooled on expectations of a further Fed rate hike, debt further falls, and US stocks continue to build last week, Hang on $Hang Seng Index (800000.HK)$ Each shot returned quite a bit. While the biotech block is hot, the writers of the past few weeks have basically been introducing different biotechnology $Biotechnology (LIST1050.HK)$ $Pharmaceutical Companies (LIST1254.HK)$ Stocks that have performed well, continue to chase the multiplier, this time also keeping an eye on a biotech stock and Wong Pharmaceuticals (13) $HUTCHMED (00013.HK)$
Wong Pharmaceutical is one of the first innovative pharmaceutical R&D companies focused on the global market. OVER THE PAST 20 YEARS, THE COMPANY HAS BUILT A FULLY INTEGRATED R&D INNOVATION PLATFORM WITH WORLD-CLASS DISCOVERY AND DEVELOPMENT CAPABILITIES TO BECOME A GLOBAL LEADER IN THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF TARGETED THERAPIES AND IMMUNOTHERAPIES FOR CANCER AND IMMUNE DISEASES. Since its founding, the company has had 13 independently discovered anti-tumor candidate drugs entering clinical trials globally, of which the first three innovative tumor drugs have now been approved — Ayute® ️ (Furuquinetine Capsules), Souteda® ️ (Sofantinetin Capsules), and Vorisa® ️ (Servotin Capsules) (Nipeds). The Company has also partnered with international pharmaceutical companies such as Aslicon and Takeda Pharmaceuticals to advance the globalization process of core products. In addition, and yellow...